<DOC>
	<DOCNO>NCT00248144</DOCNO>
	<brief_summary>The study design assess efficacy safety patient-initiated therapy famciclovir 1500 mg o.d . 750 mg b.i.d . one day treatment adult men woman recurrent herpes labialis</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Single Day Single Dose Famciclovir Treatment Recurrent Herpes Labialis</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>Patients age 18 year old A history typical recurrent herpes labialis . The subject must experience three episode cold sore last 12 month , history prodromal symptom , define patient , precede least 50 % cold sore , must also history vesicular lesion least 50 % recurrent episodes cold sore . General good health , without serious medical condition specifically normal renal hepatic function , determine patient 's account his/her medical history Women child bear potential use accept method birth control ( surgical sterilization ; intrauterine contraceptive device ; oral contraceptive ; hormone delivery system NorplantÂ® DepoProvera injection ; diaphragm combination contraceptive cream , jelly , foam ; condom combination contraceptive cream , jelly foam ) . Patients unable unwilling use one method birth control list duration study could enter study . For woman childbearing potential , negative pregnancy test ( urine ) screening require Signature informed consent document Previous herpes vaccination Patients use topical immunosuppressive agent ( include steroid , tacrolimus pimecrolimus ) near face systemic immunosuppressive agent ( include steroid , tacrolimus pimecrolimus ) within 30 day screen Patients know immunosuppressed due underlie disease ( e.g . HIV infection ) concomitant treatment ( e.g . cancer chemotherapy ) Recent history alcohol drug abuse , opinion investigator , could interfere study patient 's compliance study requirement Significant skin disease atopic dermatitis eczema would interfere assessment lesion Allergy hypersensitivity formulation contain acyclovir , penciclovir , famciclovir , and/or nucleoside analogues Women lactate breast feeding Had already randomize study Patients receive investigational drug past four week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Herpes labialis</keyword>
</DOC>